

PrEP prescription rates among adolescents and young adults (AYAs) at NJMS from 2017-2019

Paer JM¹, Mattappallil A², Bentsianov S³, Finkel D¹

¹Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ

²University Hospital, Newark, NJ

³Department of Pediatrics, Rutgers New Jersey Medical School, Newark, NJ

Background

- 2017: 21% of new HIV diagnoses occurred in AYAs (13-24), disproportionately among black and Hispanic MSM
- However, only 0.1-1.5% and 9.5-15.4% of national PrEP prescriptions have been provided to AYAs under 18 and 24, respectively, with a white male majority
- 2018: PrEP approved for use in adolescents weighing >35kg.
- Slow uptake among AYAs: lack of familiarity of PrEP and concerns about adherence, safety, confidentiality, and cost, according to limited studies on AYA provider attitudes
- Here we describe the AYA PrEP prescription rates at NJMS in the Infectious Disease Practice (IDP) and Division of Adolescent and Young Adult Medicine (DAYAM)

Methods

- Medical records queried for patients prescribed Truvada PrEP at NJMS from 2017-2019 to assess specialty-specific prescription rates and demographics of AYAs on PrEP

Results

- Of 273 PrEP patients, 2.2% (n=6) and 20.5% (n=56) under 18 and 24, respectively
- IDP and DAYAM respectively prescribed PrEP to 62.5% (n=35) and 33.9% (n=19) of AYAs
- Among AYAs on PrEP, 71.4% were black, 21.4% Hispanic, 19.6% TGW, and 85.7% MSM/TGW who have sex with men
- Most (73.7%) AYAs at DAYAM received PrEP from their PCPs compared to 5.7% at IDP

Conclusions

- AYA PrEP prescription rates at NJMS exceeded national estimates, driven by IDP/DAYAM, in contrast to national data identifying emergency, family and internal medicine providers as common AYA PrEP prescribers
- Compared to national data, our AYAs on PrEP better reflected national PrEP indications by race and HIV risk factor
- IDP/DAYAM routinely identify high-risk AYAs, assess PrEP eligibility using detailed, nonjudgmental sexual histories, and prescribe PrEP to AYAs
- Primary care should be integrated into subspecialty clinics to include PrEP in routine sexual/reproductive health services
- PCPs in other fields should expand AYA PrEP prescriptions to further engage youth in HIV prevention

Fig. 1. Annual percentage of patients receiving PrEP at NJMS, by age group.




Fig. 2. Annual percentage of AYAs receiving PrEP, by department.




Fig. 3. Percentage of AYAs prescribed PrEP by their PCP, 2017-2019.





Fig. 4. Percentage of AYAs prescribed PrEP at NJMS between 2017-2019 by (A) race, (B) gender identity, and (C) HIV transmission risk factor, % (n).



References

- Centers for Disease Control and Prevention. HIV Surveillance Report, 2017; vol 29. 2018. Available at: www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed March 4, 2020.
- Magnuson D, Hawkins T, Mera R. Adolescent use of Truvada (FTC/TDF) for HIV pre-exposure prophylaxis (PrEP) in the United States (2012 to 2017). *Journal of the International AIDS Society*. 2018 Jul 1;18-18.
- Ya-lin AH, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *Morbidity and Mortality Weekly Report*. 2018 Oct 19;67(41):1147.
- Bush S, Magnuson D, Rawlings MK, Hawkins T, McCallister S, Mera Giler R. Racial characteristics of FTC/TDF for pre-exposure prophylaxis (PrEP) users in the US. *ASM Microbe*. 2016 Jun 16:16-20.
- Centers for Disease Control and Prevention. Preventing New HIV Infections. 2019. Available at: <https://www.cdc.gov/hiv/guidelines/preventing.html>. Accessed March 4, 2020.
- Mullins TL, Zimet G, Lally M, Kahn JA, Adolescent Medicine Trials Network for HIV/AIDS Interventions. Adolescent human immunodeficiency virus care providers' attitudes toward the use of oral pre-exposure prophylaxis in youth. *AIDS patient care and STDs*. 2016 Jul 1;30(7):339-48.
- Mullins TL, Idoine CR, Zimet GD, Kahn JA. Primary care physician attitudes and intentions toward the use of HIV pre-exposure prophylaxis in adolescents in one metropolitan region. *Journal of Adolescent Health*. 2019 May 1;64(5):581-8.
- Mullins TL, Zimet G, Lally M, Xu J, Thornton S, Kahn JA, Adolescent Medicine Trials Network for HIV/AIDS Interventions. HIV care providers' intentions to prescribe and actual prescription of pre-exposure prophylaxis to at-risk adolescents and adults. *AIDS patient care and STDs*. 2017 Dec 1;31(12):504-16.
- Hart-Cooper GD, Allen I, Irwin Jr CE, Scott H. Adolescent health providers' willingness to prescribe pre-exposure prophylaxis (PrEP) to youth at risk of HIV infection in the United States. *Journal of Adolescent Health*. 2018 Aug 1;63(2):242-4.
- Straub DM, Mullins TL. Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults. *Advances in Pediatrics*. 2019 Aug 1;66:245-61.
- Hosek S, Henry-Reid L. PrEP and adolescents: the role of providers in ending the AIDS epidemic. *Pediatrics*. 2020 Jan 1;145(1).
- Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. *Ann Epidemiol* 2018;S1047-2797(17)31069-4.
- Pike C, Bekker LG. PrEP: An Opportunity to Address Unmet Adolescent Health Needs. *Pediatrics*. 2020 Jan 1;145(1).
- Saleska JL and Lee SJ. Normalization of Preexposure Prophylaxis for Adolescents: Empowerment, Not Vulnerability. *JAMA Pediatrics*. Published online August 17, 2020. doi:10.1001/jamapediatrics.2020.2545